Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010115952) INDANE DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/115952 International Application No.: PCT/EP2010/054634
Publication Date: 14.10.2010 International Filing Date: 08.04.2010
IPC:
C07C 311/07 (2006.01) ,C07C 311/24 (2006.01) ,C07D 231/18 (2006.01) ,C07D 307/64 (2006.01) ,C07D 333/34 (2006.01) ,A61P 25/00 (2006.01) ,A61K 31/18 (2006.01) ,A61K 31/341 (2006.01) ,A61K 31/381 (2006.01) ,A61K 31/415 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
01
Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
02
of an acyclic saturated carbon skeleton
07
having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
22
Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
23
having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
24
of an acyclic saturated carbon skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02
not condensed with other rings
10
having two or three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18
One oxygen or sulfur atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02
not condensed with other rings
34
having two or three double bonds between ring members or between ring members and non-ring members
56
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
64
Sulfur atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
333
Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
02
not condensed with other rings
04
not substituted on the ring sulfur atom
26
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
30
Hetero atoms other than halogen
34
Sulfur atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
18
Sulfonamides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341
not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
381
having five-membered rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
Applicants:
GILLEN, Kevin James [GB/GB]; GB (UsOnly)
GILLESPIE, Jonathan [GB/GB]; GB (UsOnly)
JAMIESON, Craig [GB/GB]; GB (UsOnly)
MACLEAN, John Kinnaird Ferguson [GB/GB]; GB (UsOnly)
MOIR, Elizabeth Margaret [GB/GB]; GB (UsOnly)
RANKOVIC, Zoran [GB/GB]; GB (UsOnly)
N.V. Organon [NL/NL]; Kloosterstraat 6 NL-5349 AB Oss, NL (AllExceptUS)
Inventors:
GILLEN, Kevin James; GB
GILLESPIE, Jonathan; GB
JAMIESON, Craig; GB
MACLEAN, John Kinnaird Ferguson; GB
MOIR, Elizabeth Margaret; GB
RANKOVIC, Zoran; GB
Agent:
MERCK SHARP & DOHME LTD.; Attn: Patent Docket Hertford Road Hoddesdon Hertfordshire EN11 9BU, GB
Priority Data:
09157744.509.04.2009EP
Title (EN) INDANE DERIVATIVES
(FR) DÉRIVÉS D'INDANE
Abstract:
(EN) The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer' s disease.
(FR) La présente invention porte sur un dérivé d'indane selon la formule I, dans laquelle les variables sont telles que définies dans la description, ou sur un sel ou solvate pharmaceutiquement acceptable de celui-ci. La présente invention porte également sur une composition pharmaceutique comprenant un desdits dérivés d'indane ou plus, et sur leur utilisation en thérapie, par exemple dans le traitement ou la prévention de maladies psychiatriques dans lesquelles une augmentation des réponses synaptiques à médiation par les récepteurs AMPA est nécessaire, comprenant la schizophrénie, la dépression et la maladie d'Alzheimer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)